Compare Neurocrine Biosciences Inc (NBIX) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Toronto-Dominion Bank — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Toronto-Dominion Bank trades at $119.29 (market cap $197.22B). The key difference: Toronto-Dominion Bank is far larger — about 12.5× Neurocrine Biosciences Inc's market cap, and Toronto-Dominion Bank pays a 2.69% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TD | |
|---|---|---|
Market Cap | $15.77B | $197.22B |
Sector | Health | Financials |
52-Week High | $185.50 | $124.80 |
52-Week Low | $123.10 | $75.86 |
Enterprise Value | $15.78B | — |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
TD trades at $120.52, down 0.91% on the day, with a neutral technical signal. The company reported strong Q3 2026 earnings of $2.74 EPS, beating estimates, driven by capital markets performance and cost controls. Revenue growth continues with 2025 revenue reaching $61.28B and net income margin of 33.51%. Analyst consensus is bullish with 9 buy ratings and no sell recommendations.
TD presents a compelling investment case with consistent earnings beats and strong profitability metrics. However, investors should monitor the volatile cash flow patterns and rising debt-to-asset ratio, which increased to 22.1 in 2024. The stock's current valuation at 17.85 P/E appears reasonable given the company's growth trajectory and dividend yield.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
